补肾益气化瘀解毒汤抗肝纤维化的临床观察

刁青蕊; 赵文霞

补肾益气化瘀解毒汤抗肝纤维化的临床观察

刁青蕊¹,
赵文霞²

1.
河南中医药大学研工部研究生院，河南郑州 450046
2.
河南中医药大学第一附属医院，河南郑州 450004

计量
- 文章访问数: 590
- HTML全文浏览量: 3
- PDF下载量: 577
- 被引次数: 0
出版历程
- 刊出日期: 2019-07-10

Clinical Observation of Bushen Yiqi Huayu Jiedu Decoction in the Treatment of Hepatic Fibrosis

DIAOQing-rui¹,
ZHAOWen-xia²

1.
Graduate School, Henan University of Chinese Medicine, Zhengzhou, 450046, China
2.
Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, 450004, China

摘要

摘要: 目的观察补肾益气化瘀解毒汤抗肝纤维化作用。方法临床选择98例肝纤维化患者，随机分为2组各49例，对照组口服鳖甲软肝片，治疗组服用补肾益气化瘀解毒汤，治疗6月后观测其临床疗效、中医证候积分、肝肾功能、肝纤维化指标、肝脾B超等指标的变化。结果治疗后，治疗组总有效率明显高于对照组（P<0.01）；2组中医证候积分，均明显下降（P<0.05~0.01），治疗组优于对照组（P<0.01）。治疗组谷丙转氨酶（ALT）、谷草转氨酶（AST）、总胆红素（TBIL）、白蛋白（ALB）含量明显下降（P<0.01），明显优于对照组（P<0.01）；治疗组透明质酸（HA）、Ⅳ型胶原（Ⅳ-C）、Ⅲ型前胶原(PCⅢ)水平明显下降（P<0.01），明显优于对照组（P<0.01）。治疗组门静脉、脾静脉内径及脾脏厚度明显缩小（P<0.05~0.01），明显优于对照组（P<0.01）;治疗组肝脏硬度值明显下降，优于对照组（P<0.01）。结论补肾益气化瘀解毒汤抗肝纤维化效果确切。
- 肝纤维化 /
- 补肾益气化瘀解毒汤 /
- 中医药治疗
Abstract: OBJECTIVE To observe the effect of Bushen Yiqi Huayu Jiedu Decoction on anti-hepatic fibrosis. METHODS 98 patients with hepatic fibrosis were randomly divided into two groups， 49 in each group. The control group was given Biejia Ruangan Tablet. The treatment group was given Bushen Yiqi Huayu Jiedu Decoction. After six months of treatment， the changes of clinical efficacy， TCM syndrome score， liver and kidney function， liver fibrosis index， liver and spleen B ultrasound were observed. RESULTS After treatment， the total effective rate of the treatment group was significantly higher than that of the control group (P<0.01); TCM syndrome scores in the two groups were significantly decreased (P<0.05， P<0.01)， and the treatment group was better than that of the control group (P<0.01). The contents of alanine aminotransferase (ALT)， aspartate aminotransferase (AST)， total bilirubin (TBIL)， albumin (ALB) in the treatment group decreased significantly (P<0.01)， which was more obvious than that in the control group (P<0.01). The levels of hyaluronic acid (HA)， collagen Ⅳ(Ⅳ-C)， procollagen Ⅲ(PCⅢ) in the treatment group decreased significantly (P<0.01)， which was better than that in the control group (P<0.01)， the diameters of portal vein， splenic vein and the thickness of spleen in the treatment group decreased significantly (P<0.05， P<0.01)， which was significantly better than that of the control group (P<0.01). After treatment， the B-ultrasound grade of the two groups decreased significantly (P<0.01). The liver hardness value of the treatment group was significantly lower than that of the control group(P<0.05). CONCLUSION Bushen Yiqi Huayu Jiedu Decoction shows definite anti-hepatic fibrosis effect.
- hepatic fibrosis /
- Bushen Yiqi Huayu Jiedu Decoction /
- Chinese medicine treatment

HTML全文

参考文献(11)

[1]	NIETO N， FRIEDMAN SL， CEDERBAUM AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species [J]. Hepatology，2012，35(1):62-73.
[2]	姜一鸣，姜学连，刘新军，等.中医综合治疗慢性乙型肝炎肝纤维化优化方案的研究[J].世界中西医结合杂志，2015，10(1):75-76.
[3]	徐列明.肝纤维化或肝硬化“正虚血瘀”中医病机的临床观察和研究[J].世界科学技术——中医药现代化，2016，18(9):1465-1470.
[4]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南[J].临床肝胆病杂志，2015，31(12):1941-1958.
[5]	肝硬化临床诊断、中医辨证和疗效评定标准（试行方案）[J].中国中西医结合杂志，1994，14(4):237-238.
[6]	中国中西医结合学会消化系统疾病专业委员会.肝硬化临床诊断、中医辨证和疗效评定标准(试行方案)[C].重庆：中华中医药学会第11届肝胆病学术会议，2003.
[7]	李汨，聂青和，龙振昼，等.Fibmscan对原发性肝癌的诊断价值[J].中华超声影像学杂志，2016，25(10):865-869.
[8]	慕永平，张笑，范魏巍，等.黄芪总皂苷通过抑制Notch信号通路抗胆汁性肝纤维化的作用机制[J].中华肝脏病杂志，2017，25(8):575-578.
[9]	张润萍，宁宇，刘娜，等.益气活血中药对放射性肝损伤的保护作用及对肝纤维化指标的影响[J].中国临床医生杂志，2017，45(10):112-114.
[10]	王志旺，付晓艳，程小丽，等.育阴软肝颗粒剂对肝纤维化大鼠TGF-β1表达的影响[J].中国应用生理学杂志，2018，34(2):169-172.
[11]	郝瑞军.恩替卡韦联合扶正化瘀胶囊治疗乙型肝炎后肝硬化失代偿期疗效观察[J].中国药物与临床，2017，17(10):1507-1509.